Effect of statins therapy on the levels of serum proprotein convertase subtilisin/kexin 9 in acute ST elevation myocardial infarction
WAN Peng1, FU Qiang2, ZHANG Qian2, WEI Peng2, ZHU Ke2, LU Yi2, SUI Jian1
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Cardiology, Xuzhou Central Hospital, Xuzhou Jiangsu 221009, China)
Abstract:Objective: To observe the changes in levels of serum proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with acute ST elevation myocardial infarction (STEMI) after statin therapy. Methods: A total of 167 consecutive cases of patients with STEMI were selected. A statin therapy was administered to all patients; in addition, another 50 cases of healthy adults were included as the control group. In STEMI group upon admission, as well as 1 and 4 weeks after statin therapy,and control group, serum PCSK9, blood lipid, troponin I, hsCRP and other indices were determined. Results: PCSK9 level of STEMI group on admission was higher than that of control group (P<0.01), which significantly declined 1 week after statin therapy(P<0.01) and was not significantly different from control group(P=0.135), and that at week 4 of statin therapy was significantly reduced comparing with group upon admission(P<0.01), but was much higher than that of 1 week after statin therapy(P<0.01) and control group(P<0.01). The LDLC level of STEMI group on admission was significantly higher than that of control group (P<0.01), which declined one week after statin therapy(P<0.01) and was not significantly different from control group(P=0.549); and that in STEMI group 4 weeks after statin therapy was further reduced compared with that of 1 week after statin therapy(P<0.01). Conclusion: Serum PCSK9 level in STEMI patients presents dynamic changes within 4 weeks after statin therapy. The declined blood LDLC concentration may facilitate the elevation of PCSK9 level in vivo in a manner of negative feedback, while the elevated PCSK9 in turn will reregulate the plasma LDLC level through negative feedback, and accordingly takes part in the process of cholesterol escape after statin therapy.
收稿日期: 2016-10-20
通讯作者:
眭建(通讯作者),教授,硕士生导师,E-mail:chongci320@163.com
作者简介: 万鹏(1987—),男,硕士研究生;
引用本文:
万鹏1, 付强2, 张倩2, 魏鹏2, 朱可2, 陆奕2, 眭建1. 他汀类药物对急性ST段抬高型心肌梗死患者PCSK9含量的影响[J]. 江苏大学学报:医学版, 2017, 27(01): 64-68.
WAN Peng1, FU Qiang2, ZHANG Qian2, WEI Peng2, ZHU Ke2, LU Yi2, SUI Jian1. Effect of statins therapy on the levels of serum proprotein convertase subtilisin/kexin 9 in acute ST elevation myocardial infarction. Journal of Jiangsu University(Medicine Edition), 2017, 27(01): 64-68.
[1\]中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南\[J\]. 中华心血管病杂志, 2015, 43(5): 380-393.\[2\]Seidah NG, Benjannet S, Wickham L, et al.The secretory proprotein convertase neural apoptosisregulated convertase 1(NARC1): liver regeneration and neuronal differentiation\[J\]. Proc Natl Acad Sci USA, 2003, 100(3): 928-933.\[3\]Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction\[J\]. Eur Heart J, 2012, 33(20): 2551-2567.\[4\]Chen Z, Zhang X, Ma G, et al. Association study of four variants in KCNQl with type 2 diabetes mellitus and premature coronary arterydisease in a Chinese population \[J\]. Mol Biol Rep, 2010, 37(1): 207-212.\[5\]Wasko BM, Smits JP, Shull LW, et al. A novel bisphosphonate inhibitor of synthase combined with a statin or a nitrogenousbisphosphonate in vitro\[J\]. J Lipid Res, 2011,52(11): 1957-1964.\[6\]Tibolla G, Norata GD, Artali R,et al. Proprotein convertase subtilisin /kexin type 9(PCSK9) : from structurefunction relation to therapeutic inhibiton\[J\]. Nutr Metab Cardiovas Dis, 2011, 21(11): 835-843.\[7\]Cheung BM,Lam KS.Is intensive LDLcholesterol lowering beneficial and safe?\[J\]. Lancet, 2010, 376(9753): 1622-1624.\[8\]Sasaki J,Otonari T,Sawayama Y,et al.Doubledose pravastatin versus addon ezetimibe with lowdose pravastatineffects on LDL cholesterol,cholesterol absorption,and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study)\[J\]. J Atheroscler Thromb, 2012, 19(5): 485-493.\[9\]Nicholls SJ, BrandrupWognsen G, Palmer M, et al. Metaanalysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)\[J\]. Am J Cardiol, 2010, 105(1): 69-76.\[10\]Yeshurun D, Slobodin G, Keren D, et al. Statin escape phenomenon: Does it really exist?\[J\]. Eur J Intern Med, 2005,16(3):192-194.\[11\]Ota T, Ishii H, Suzuki S, et al. Impact of the statin escape phenomenon on longterm clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS)\[J\]. Atherosclerosis, 2015, 242(1): 155-160.\[12\]廖玉华,魏晶晶.他汀和PCSK9抑制剂调节LDLC合成与清除代谢的临床荟萃分析\[J\].临床心血管病杂志,2016,32(6):537-540.\[13\]Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosisregulated convertase 1(NARC1):liver regeneration and neuronal differentiation\[J\]. P Natl Acad Sci USA, 2003, 100(3): 928-933.\[14\]Costet P,Cariou B,Lambent G,et al.Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory elementbinding protein 1c\[J\]. J Biol Chem, 2006, 281(6): 6211-6218.\[15\]Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia\[J\].Nat Struct Mol Biol, 2007, 14(5): 413-419.\[16\]Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase(PC) PCSK9 is inactivated by fiirin and/ or PC5/6A. Functional consequences of natural mutations and posttranslatinal modifications\[J\]. J Biol Chem, 2006, 281(41): 30561-30572.\[17\]Leren TP. Mutations in the pcsk9 gene in Norwegian subjects with automal dominant hypercholesterolemia\[J\]. Clin Genet, 2004, 65(5): 419-422.\[18\]Shioji K, Mannami T, Kokubo Y, et al. Genetic variants in pcsk9 affect the cholesterol level in Japanese\[J\]. J Hum Genet, 2004, 49(2):109-114.\[19\]Nassoury N,Blasiole DA, Oler AT,et al.The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR\[J\].Traffic,2007,9(8):718-732.